堀井 俊宏

Publication

• (1) Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5-10-Year-Old Burkinabe Children Naturally Exposed to Malaria. Nebie I. et. al. Vaccines (Basel). (2024)12(2):166.
• (2) Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial. Ouédraogo A. et. al. Front Immunol. (2023)14:1267372.
• (3) Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children. Bougouma EC. et. al. Front Immunol. (2022)13:978591.
• (4) Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5. Tougan T. et. al. Sci Rep. (2018)8(1):5052.
• (5) Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. Palacpac N.M.Q. et. al. PLoS One. (2013)8(5):e64073.
• (6) Evidences of Protection Against Blood-stage Infection of Plasmodium falciparum by the Novel Protein Vaccine SE36. Horii T. et. al. Parasitol Int. (2010)59(3):380-6.